Treatment of visceral leishmaniasis (kala-azar): A decade of progress and future approaches
Open Access
- 1 January 2000
- journal article
- review article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 4 (3) , 158-177
- https://doi.org/10.1016/s1201-9712(00)90078-x
Abstract
No abstract availableKeywords
This publication has 159 references indexed in Scilit:
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999
- Visceral Leishmaniasis (Kala‐azar) in Solid Organ Transplantation: Report of Five Cases and ReviewClinical Infectious Diseases, 1999
- Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United KingdomTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992
- Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, IndiaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992
- A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumoursZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Is leishmaniasis ever cured?Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992
- Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatmentTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992
- Treatment of Visceral Leishmaniasis with Pentavalent Antimony and Interferon GammaNew England Journal of Medicine, 1990
- Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis.Journal of Clinical Investigation, 1985
- Impaired Production of Lymphokines and Immune (Gamma) Interferon in the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1984